Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03315689 · ClinicalTrials.gov registry record · Phase 2
Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT)
A Phase 2 study, sponsored by Aclaris Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT03315689 is a Phase 2 study that has completed, run by Aclaris Therapeutics. The registered enrollment target is 11 participants.
The verdict
NCT03315689, a Phase 2 study, has completed, sponsored by Aclaris Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
The primary objective is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of ATI-50002 Topical Solution compared to vehicle in subjects with AU and AT.
Interventions
- DRUG Vehicle
- DRUG ATI-50002
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2017-12-14 |
| Est. Completion | 2019-06-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03315689
The ClinicalTrials.gov registry entry for NCT03315689 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aclaris Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle is the first listed.
NCT03315689 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03315689 about?
NCT03315689 is a clinical study titled "Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT)". The primary objective is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of ATI-50002 Topical Solution compared to vehicle in subjects with AU and AT.
What is the current status of trial NCT03315689?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2017-12-14. Estimated completion is 2019-06-20.
What interventions are being tested in trial NCT03315689?
The interventions under investigation include: Vehicle (DRUG), ATI-50002 (DRUG).
Who is sponsoring clinical trial NCT03315689?
This trial is sponsored by Aclaris Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.